Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.76 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CCR6 | P51684 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30168150 | 0.83 | ALDH1A1 (0.67) | ALDH1A1MAPTL3MBTL1KMT2AHTT | |
| SCHEMBL10674588 | 0.83 | ALDH1A1 (0.67) | ALDH1A1MAPTL3MBTL1KMT2AHTT | |
| SCHEMBL13216550 | 0.83 | ALDH1A1 (0.55) | ALDH1A1MAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL13216555 | 0.82 | ALDH1A1 (0.56) | ALDH1A1MAPTKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL29106604 | 0.81 | MAPT (0.66) | ALDH1A1MAPTL3MBTL1KMT2AHTT | |
| SCHEMBL16730282 | 0.80 | MAPT (0.65) | ALDH1A1MAPTL3MBTL1KMT2AHTT | |
| SCHEMBL2941803 | 0.79 | MAPT (0.56) | ALDH1A1MAPTKMT2AHTTMEN1 | |
| SCHEMBL14192526 | 0.79 | ALDH1A1 (0.73) | ALDH1A1MAPTL3MBTL1KMT2AHTT | |
| SCHEMBL3271853 | 0.78 | ALDH1A1 (0.68) | ALDH1A1MAPTL3MBTL1KMT2AHTT | |
| SCHEMBL4490833 | 0.78 | ALDH1A1 (0.68) | ALDH1A1MAPTL3MBTL1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210864-A1 | PROCESS FOR THE PREPARATION OF N-ARYLMORPHOLINONES | DORSCH DIETER | 2010-08-19 | — | — | US | disclosed |
| US-7687624-B2 | Process for the production of N-arylmorpholinones | MERCK PATENT GMBH (DE) | 2010-03-30 | — | — | US | disclosed |
| EP-1654240-B1 | METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES | MERCK PATENT GMBH (DE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060217550-A1 | One pot process; cyclization; 4-(4-nitrophenyl)-3-oxomorpholine; Factor Xa inhibitors; , myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens | MERCK PATENT GMBH (DE) | 2006-09-28 | — | — | US | disclosed |
| EP-1654240-A1 | METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES | MERCK PATENT GmbH (DE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005016899-A1 | METHOD FOR PRODUCTION OF N-ARYL MORPHOLINONES | MERCK PATENT GMBH (DE) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210864-A1 | PROCESS FOR THE PREPARATION OF N-ARYLMORPHOLINONES | CYP1A1, CYP1B1, OPRM1 | ALDH1A1 264/4885MAPT 1388/4885L3MBTL1 4855/4885 |
| US-20060217550-A1 | One pot process; cyclization; 4-(4-nitrophenyl)-3-oxomorpholine; Factor Xa inhibitors; , myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and claudicatio intermittens | PLAT, PCSK9, SERPINE1 | ALDH1A1 2931/4885MAPT 4446/4885L3MBTL1 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.